Cargando…

Overexpression of MutL homolog 1 and MutS homolog 2 proteins have reversed prognostic implications for stage I–II colon cancer patients

BACKGROUND: The outcome of colon cancer patients without lymph node metastasis is heterogeneous. Searching for new prognostic markers is warranted. METHODS: One hundred twenty stage I–II colon cancer patients who received complete surgical excision during 1995–2004 were selected for this biomarker s...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Shih-Chiang, Huang, Shiu-Feng, Chen, Ya-Ting, Chang, Yu, Chiu, Yu-Ting, Chang, Il-Chi, Wu, Hong-Dar Isaac, Chen, Jinn-Shiun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Chang Gung University 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6138591/
https://www.ncbi.nlm.nih.gov/pubmed/28411881
http://dx.doi.org/10.1016/j.bj.2017.01.004
_version_ 1783355358552522752
author Huang, Shih-Chiang
Huang, Shiu-Feng
Chen, Ya-Ting
Chang, Yu
Chiu, Yu-Ting
Chang, Il-Chi
Wu, Hong-Dar Isaac
Chen, Jinn-Shiun
author_facet Huang, Shih-Chiang
Huang, Shiu-Feng
Chen, Ya-Ting
Chang, Yu
Chiu, Yu-Ting
Chang, Il-Chi
Wu, Hong-Dar Isaac
Chen, Jinn-Shiun
author_sort Huang, Shih-Chiang
collection PubMed
description BACKGROUND: The outcome of colon cancer patients without lymph node metastasis is heterogeneous. Searching for new prognostic markers is warranted. METHODS: One hundred twenty stage I–II colon cancer patients who received complete surgical excision during 1995–2004 were selected for this biomarker study. Immunohistochemical method was used to assess p53, epidermal growth factor receptor, MLH1, and MSH2 status. KRAS mutation was examined by direct sequencing. RESULTS: Thirty three patients (27.5%) developed metachronous metastasis during follow up. By multivariate analysis, only female gender (p = 0.03), high serum carcinoembryonic antigen (CEA) level (≧5 ng/ml) (p = 0.04), and MLH1 overexpression (p = 0.003) were associated with the metastasis group. The 5-year-survival rate were also significantly lower for female gender (71.7% versus 88.9%, p = 0.025), high CEA level (64.9% versus 92.4%, p < 0.001), and MLH1 overexpression (77.5% versus 94.4%, p = 0.039). In contrast, MSH2 overexpression was associated with better survival, 95.1% versus 75.5% (p = 0.024). CONCLUSIONS: The reversed prognostic implications in the overexpression of MLH1 and MSH2 for stage I–II colon cancer patients is a novel finding and worthy of further confirmation.
format Online
Article
Text
id pubmed-6138591
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Chang Gung University
record_format MEDLINE/PubMed
spelling pubmed-61385912018-09-27 Overexpression of MutL homolog 1 and MutS homolog 2 proteins have reversed prognostic implications for stage I–II colon cancer patients Huang, Shih-Chiang Huang, Shiu-Feng Chen, Ya-Ting Chang, Yu Chiu, Yu-Ting Chang, Il-Chi Wu, Hong-Dar Isaac Chen, Jinn-Shiun Biomed J Original Article BACKGROUND: The outcome of colon cancer patients without lymph node metastasis is heterogeneous. Searching for new prognostic markers is warranted. METHODS: One hundred twenty stage I–II colon cancer patients who received complete surgical excision during 1995–2004 were selected for this biomarker study. Immunohistochemical method was used to assess p53, epidermal growth factor receptor, MLH1, and MSH2 status. KRAS mutation was examined by direct sequencing. RESULTS: Thirty three patients (27.5%) developed metachronous metastasis during follow up. By multivariate analysis, only female gender (p = 0.03), high serum carcinoembryonic antigen (CEA) level (≧5 ng/ml) (p = 0.04), and MLH1 overexpression (p = 0.003) were associated with the metastasis group. The 5-year-survival rate were also significantly lower for female gender (71.7% versus 88.9%, p = 0.025), high CEA level (64.9% versus 92.4%, p < 0.001), and MLH1 overexpression (77.5% versus 94.4%, p = 0.039). In contrast, MSH2 overexpression was associated with better survival, 95.1% versus 75.5% (p = 0.024). CONCLUSIONS: The reversed prognostic implications in the overexpression of MLH1 and MSH2 for stage I–II colon cancer patients is a novel finding and worthy of further confirmation. Chang Gung University 2017-02 2017-03-14 /pmc/articles/PMC6138591/ /pubmed/28411881 http://dx.doi.org/10.1016/j.bj.2017.01.004 Text en © 2017 Chang Gung University. Publishing services by Elsevier B.V. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Huang, Shih-Chiang
Huang, Shiu-Feng
Chen, Ya-Ting
Chang, Yu
Chiu, Yu-Ting
Chang, Il-Chi
Wu, Hong-Dar Isaac
Chen, Jinn-Shiun
Overexpression of MutL homolog 1 and MutS homolog 2 proteins have reversed prognostic implications for stage I–II colon cancer patients
title Overexpression of MutL homolog 1 and MutS homolog 2 proteins have reversed prognostic implications for stage I–II colon cancer patients
title_full Overexpression of MutL homolog 1 and MutS homolog 2 proteins have reversed prognostic implications for stage I–II colon cancer patients
title_fullStr Overexpression of MutL homolog 1 and MutS homolog 2 proteins have reversed prognostic implications for stage I–II colon cancer patients
title_full_unstemmed Overexpression of MutL homolog 1 and MutS homolog 2 proteins have reversed prognostic implications for stage I–II colon cancer patients
title_short Overexpression of MutL homolog 1 and MutS homolog 2 proteins have reversed prognostic implications for stage I–II colon cancer patients
title_sort overexpression of mutl homolog 1 and muts homolog 2 proteins have reversed prognostic implications for stage i–ii colon cancer patients
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6138591/
https://www.ncbi.nlm.nih.gov/pubmed/28411881
http://dx.doi.org/10.1016/j.bj.2017.01.004
work_keys_str_mv AT huangshihchiang overexpressionofmutlhomolog1andmutshomolog2proteinshavereversedprognosticimplicationsforstageiiicoloncancerpatients
AT huangshiufeng overexpressionofmutlhomolog1andmutshomolog2proteinshavereversedprognosticimplicationsforstageiiicoloncancerpatients
AT chenyating overexpressionofmutlhomolog1andmutshomolog2proteinshavereversedprognosticimplicationsforstageiiicoloncancerpatients
AT changyu overexpressionofmutlhomolog1andmutshomolog2proteinshavereversedprognosticimplicationsforstageiiicoloncancerpatients
AT chiuyuting overexpressionofmutlhomolog1andmutshomolog2proteinshavereversedprognosticimplicationsforstageiiicoloncancerpatients
AT changilchi overexpressionofmutlhomolog1andmutshomolog2proteinshavereversedprognosticimplicationsforstageiiicoloncancerpatients
AT wuhongdarisaac overexpressionofmutlhomolog1andmutshomolog2proteinshavereversedprognosticimplicationsforstageiiicoloncancerpatients
AT chenjinnshiun overexpressionofmutlhomolog1andmutshomolog2proteinshavereversedprognosticimplicationsforstageiiicoloncancerpatients